Investment Rating - The report assigns an "Overweight" rating to the healthcare industry [1]. Core Viewpoints - The establishment of the medical insurance prepayment system is expected to enhance operational efficiency in the healthcare sector [1][2]. - The prepayment system will alleviate the financial pressure on medical institutions, thereby improving their operational efficiency and promoting stable operations for pharmaceutical and consumable companies [1][2]. - The report expresses optimism about the development prospects of the healthcare service industry, recommending companies such as Haijia (603939CH, Buy rating, target price RMB 47.90), Gushengtang (2273 HK, Buy rating, target price HK$ 73.95), and Jinxin Reproductive (1951 HK, Buy rating, target price HK$ 4.78) [3]. Summary by Sections Medical Insurance Prepayment System - The prepayment system aims to help medical institutions manage cash flow pressures and enhance service capabilities, specifically for drug and consumable expenditures [2]. - The prepayment amount will be based on the average monthly expenditure of the medical insurance fund over the previous 1-3 years, adjusted according to the annual comprehensive evaluation and credit rating of the medical institutions [2]. Industry Outlook - The report anticipates that the implementation of the prepayment system will accelerate cash flow in the Chinese healthcare service industry, leading to improved operational efficiency [3].

Industry Investment Rating - Overweight rating for the pharmaceutical retail industry [1] Core Views - The pharmaceutical retail business has shown strong revenue growth resilience in the first 8 months of 2024 [1] - The pharmaceutical retail industry is expected to achieve improved profit margins in the future, with Yifeng Pharmacy being the top recommendation [1][2] - The industry is transitioning from store expansion to profitability enhancement, maintaining long-term growth potential [2] Revenue Growth and Channel Analysis - From January to August 2024, the pharmaceutical retail market in China reached a sales scale of RMB 3,244 billion, with a year-on-year growth rate of 1.4% [1] - Retail pharmacies (including O2O) accounted for 87.0% of the market, with a year-on-year growth rate of 0.3% [1] - E-commerce B2C accounted for 13.0% of the market, with a year-on-year growth rate of 9.6%, and its market share increased by 1.0% compared to the previous year [1] - In July and August 2024, offline retail pharmacy revenue grew by 2% and 5% year-on-year, respectively, indicating a clear improvement in the performance of physical pharmacies [2] Channel Differentiation and Product Focus - Retail pharmacies, due to their professional nature, focus on categories such as oncology drugs, cardiovascular drugs, and hypertension medications [2] - Online platforms, leveraging privacy, prioritize categories like dermatological drugs and urological medications [2] - O2O, as an emerging field, is increasingly important for retail growth, particularly for acute medication needs such as cold medicines, cough suppressants, and systemic anti-infective drugs [2] Company Recommendation - Yifeng Pharmacy (603939CH) is recommended with a "Buy" rating and a target price of RMB 47.90 [2]

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------------------|-------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------|------------------------------------------|------------------|--- ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of US$28.90, representing a potential upside of 15% from the current price of US$25.06 [1][4][12]. Core Insights - The company is expected to deliver between 160,000 to 170,000 new vehicles in Q4 2024, with projected revenue ranging from RMB 432 billion to RMB 459 billion, indicating a year-on-year growth of 3.5% to 10% [4][6]. - The gross margin for Q3 2024 improved significantly, reaching 21.5%, driven by a decrease in vehicle costs, despite some offset from the increased delivery of lower-priced models [5][10]. - The report highlights a substantial increase in operating profit for Q3 2024, which reached RMB 34.3 billion, a remarkable growth of 633.4% quarter-on-quarter [5][10]. Financial Performance Summary - The company reported Q3 2024 revenue of RMB 428.7 billion, a year-on-year increase of 23.6% and a quarter-on-quarter increase of 35.3% [5][9]. - The projected earnings per share (EPS) for 2024 is RMB 11.12, reflecting a 38% increase from previous estimates [1][11]. - The forecasted revenue for 2024 is RMB 145,464 million, with a gross profit of RMB 30,503 million, indicating a gross margin of 21.0% [8][11]. Adjustments and Forecasts - The report adjusts the company's 2024-2026 gross margin estimates upward to reflect the ongoing decrease in unit costs, with the gross margin expected to range from 21.0% to 23.2% [7][10]. - Non-GAAP net profit estimates for 2024, 2025, and 2026 have been revised to RMB 108.9 billion, RMB 147.0 billion, and RMB 191.2 billion respectively, showing a growth trajectory [10][11]. - The company is expected to maintain a steady monthly sales volume exceeding 50,000 units, supported by the upcoming BEV new vehicle cycle in 2025 [12][10].

Investment Rating - The report maintains a "Buy" rating for China Merchants Bank-H (3968 HK) with a target price of HK$48.90, representing a potential upside of 29% from the current price of HK$38.00 [1][5]. Core Views - The bank's 3Q24 earnings met expectations, benefiting from effective cost control that offset declines in interest and commission income. The adjusted net profit for 3Q24 was RMB 38.4 billion, a year-on-year increase of 0.8% [6][10]. - Revenue growth continues to slow, with a year-on-year decline of 2.6%, primarily due to a 14 basis point decrease in net interest margin, which offset a 4.7% increase in loans [6][12]. - The bank's asset quality showed relative improvement, with a non-performing loan ratio stable at 0.94% and a high coverage ratio of 432.2% [7][14]. - The outlook for 4Q24 and 2025 suggests a continued decline in net interest margin, although the pace of decline is expected to slow. Credit demand is anticipated to recover in 2025 [8][12]. Summary by Sections Earnings Performance - In 3Q24, adjusted net profit was RMB 38.4 billion, with a year-to-date adjusted net profit of RMB 111.2 billion, flat year-on-year [6][10]. - The bank's total revenue for 3Q24 was RMB 79.1 billion, down 2.6% year-on-year, driven by a decrease in net interest income and commission income [13]. Financial Metrics - The bank's cost-to-income ratio improved to 32.6%, down from 34.3% in 2Q24, indicating better cost management [7][14]. - The core Tier 1 capital ratio increased by 87 basis points to 14.73%, reflecting strengthened capital levels [7][14]. Future Outlook - The bank expects a decline in net interest margin in 4Q24, but the decrease is projected to be less severe than in 2024. Loan growth is expected to exceed 2024 levels, particularly in retail loans [8][12]. - The bank's ability to generate positive growth in commission income in 2025 will depend on regulatory decisions regarding fee reductions [8][12].

Investment Rating - The report assigns a "Hold" rating to the company with a target price of RMB 25.90, reflecting a 15% decrease from the previous target price of RMB 30.62 [1][2] Core Insights - The company's performance in the first three quarters of 2024 was below expectations, with revenue and net profit declining by 6.8% and 12.4% year-on-year, respectively [1][2] - The "old-for-new" policy has shown significant effects, but there is still a lack of long-term logic, leading to concerns about the risk-reward ratio [1][2] - The company is expected to see a revenue growth of 3% year-on-year in Q4 2024, driven by the "old-for-new" policy and improved online channel revenue growth [1][2] Financial Performance Summary - Revenue for 2024E is adjusted to RMB 10,749 million, a decrease of 14.1% from previous estimates [2] - The net profit for 2024E is revised down to RMB 1,662 million, reflecting a 25.7% reduction [2] - The EPS for 2024E is adjusted to RMB 1.76, down 25.3% from earlier projections [2] Market Position and Valuation - The current market capitalization of the company is approximately USD 3,199 million [1] - The company’s P/E ratio for 2025E is projected at 14 times, with a target price corresponding to this valuation [1][2] - The stock price has a potential upside of 8% from the current price of RMB 24.07 [1]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$6.95, representing a 24% increase from the previous target price of HK$5.61 [1][7]. Core Insights - The company's brand, Xtep, has shown a month-to-date (MTD) revenue growth of over 10% in October, indicating a strong performance that is expected to meet the annual guidance [4][6]. - For the fiscal year 2024, the overall revenue and net profit attributable to the parent company are projected to grow by 1.5% and 21.3%, reaching RMB 14.56 billion and RMB 1.25 billion, respectively [6][9]. - The report highlights that the company's inventory and discount levels are healthy, with expectations for continued improvement in gross margin [5][6]. Financial Projections - The revenue forecast for 2024 has been adjusted to RMB 14.56 billion, reflecting a 3.6% decrease from previous estimates, while the net profit forecast has been adjusted to RMB 1.25 billion, a decrease of 3.0% [9]. - The earnings per share (EPS) for 2024 is projected at RMB 0.47, with subsequent years showing growth to RMB 0.53 in 2025 and RMB 0.59 in 2026 [8][9]. - The report anticipates a gross margin improvement of 2.1 percentage points to 44.2% for 2024, alongside a net profit margin increase of 1.4 percentage points to 8.6% [6][9].

Investment Rating - The report maintains a "Buy" rating for Eve Energy (300014 CH) with a target price of RMB64.30, representing a 30% upside from the current price of RMB49.44 [1][2] - The target price has been revised upward by 16% from RMB55.30 to RMB64.30 [2] Core Views - Eve Energy's 3Q24 gross margin improved significantly to 19.0%, driven by higher capacity utilization in power and energy storage batteries, as well as lower raw material costs [4] - The company's overseas energy storage business is expected to grow significantly in 2025/26, with the first global cooperative project (ACT) progressing smoothly [5] - The report forecasts a 40.2% YoY growth in net profit attributable to shareholders in 2025, supported by improving capacity utilization and strong demand for energy storage and consumer batteries [6] Financial Performance - 3Q24 revenue was RMB12.39 billion, down 1.3% YoY but up 0.4% QoQ [4] - 3Q24 gross profit reached RMB2.355 billion, with a gross margin of 19.0%, up 3.4 percentage points QoQ [4] - Non-GAAP net profit attributable to shareholders grew 25.5% QoQ to RMB1.0 billion in 3Q24 [4] - The company's energy storage battery shipments reached 35.7GWh in the first three quarters of 2024, up 115.6% YoY [5] Business Outlook - Power battery shipments are expected to increase in 4Q24 with new customer Leapmotor's volume contribution [5] - The ACT project, a joint venture with Cummins, Daimler Truck, and PACCAR, is on track to start production in 2026 with an annual capacity of 21GWh [5] - Consumer batteries have been operating at full capacity for six consecutive months, with the Malaysia factory progressing well [5] Valuation - The battery business is valued at 19x 2025E P/E, implying a valuation of RMB112.4 billion [11][12] - Including the stake in Smoore International, the total valuation is RMB131.6 billion, leading to the target price of RMB64.30 [11][12] - The 2025E EPS is forecasted at RMB3.19, representing a 40.2% YoY growth [6][12] Peer Comparison - Eve Energy's 2025E P/E of 15.5x is slightly below the peer average of 19x, with a PEG ratio of 0.39 [13] - The company's valuation multiples are comparable to industry leaders like CATL (22x 2024E P/E) and Gotion High-Tech (28x 2024E P/E) [13]

Investment Rating - The report initiates coverage with a "Buy" rating for Micron Technology (MU US) and sets a target price of $148.00 [1][5][6]. Core Insights - Micron is expected to rapidly iterate its HBM products, leading to revenue and profit margins that may exceed expectations [1]. - The HBM business market share is projected to continue increasing from 2024 to 2026, with significant capital expenditures planned to enhance production capacity [2][16]. - The high demand for HBM products, particularly driven by AI applications, is anticipated to support pricing stability in the high-end segment [3][15]. - Operating profit margins for Micron are expected to improve significantly in the 2025 and 2026 fiscal years, driven by a higher contribution from HBM revenue and recovery in DRAM and NAND margins [4][17]. Summary by Sections HBM Business Outlook - Micron's HBM market share is expected to rise to 11% by 2025, supported by increased capital expenditures and advancements in HBM3E and HBM4 technologies [2][16]. - The global demand for HBM driven by AI chips is projected to reach 23.6 billion GB by the end of 2025, while supply from Micron, Samsung, and SK Hynix is expected to be 20.1 billion GB, indicating a supply shortage [3][15]. Financial Projections - Revenue forecasts for Micron show significant growth, with expected revenues of $38.65 billion in 2025 and $44.85 billion in 2026 [5][8]. - The GAAP operating profit margin is projected to reach 27.5% in 2025 and 32.0% in 2026, driven by an increase in HBM revenue contribution [4][17]. Valuation and Target Price - The target price of $148.00 reflects a substantial upside potential of 41% from the current price of $105.05, based on a sum-of-the-parts (SOTP) valuation approach [5][6][19]. - The valuation includes estimates for DRAM, NAND, and other business segments, along with net cash of $9.08 billion [19]. Market Dynamics - The report highlights that the high-end HBM products will remain in short supply through 2025-2026, supporting price stability [3][15]. - Micron's strategy includes a focus on long-term contracts with customers, which has increased the predictability of revenue and operational stability [28][30]. Product Development and Innovation - Micron is advancing its product offerings by skipping HBM3 and directly developing HBM3E and HBM4, with successful validation from Nvidia [18][34]. - The company is also enhancing its production efficiency and reducing costs through technological innovations in DRAM and NAND manufacturing processes [24][26].

Investment Rating - Tesla (TSLA US) is rated as "Buy" with a target price of US$270 00, indicating a 26% upside potential from the current price of US$213 65 [2] Core Views - Tesla's 3Q24 gross margin improved significantly to 19 8%, up 1 8/1 9 percentage points YoY/QoQ, driven by a 4 6% QoQ reduction in vehicle cost to US$35,106 [3] - Elon Musk expects 20-30% growth in new vehicle sales in 2025, with Cybercab production reaching 2 million units annually in the future [3][4] - Tesla plans to launch a cheaper model priced below US$30,000 in 2025, and FSD V13 is expected to be released soon, improving intervention intervals by 5-6 times [4] - The Lathrop factory is rapidly developing, and the Shanghai factory is expected to start shipments in 1Q25, with fixed energy storage product capacity reaching 100GWh annually [4] Financial Performance - 3Q24 revenue was US$25 18 billion, up 7 8% YoY but down 1 2% QoQ, with operating profit reaching US$2 72 billion, up 54 0%/69 3% YoY/QoQ [3] - 3Q24 GAAP/non-GAAP net income was US$2 17/2 51 billion, up 16 9%/8 1% YoY, with operating cash flow and free cash flow at US$6 26/2 74 billion [3] - 2024E/2025E/2026E EPS is forecasted at US$2 82/3 54/4 51, with 2024E EPS revised up by 7% [2] - 2024E/2025E/2026E revenue is projected at US$98 87/117 18/140 12 billion, with non-GAAP net income at US$9 05/12 21/15 56 billion [4][7] Valuation - Tesla's 2024E P/E for the automotive business is maintained at 90x, while the energy storage business is valued at 10x P/S, resulting in a target price of US$270 00 [8][9] - The automotive business is valued at US$708 82 billion, energy storage at US$96 13 billion, and services/other at US$52 51 billion, totaling US$857 46 billion [9] Industry Outlook - The automotive and auto parts sector is rated as "Overweight" [1]